StreetAlpha.app
Home › Stocks › OCUL

Ocular Therapeutix, Inc (OCUL)

Healthcare
$6.02
▲ +0.17%
LAST CLOSE · NOV 17

Ocular Therapeutix develops eye treatments, including AXPAXLI, an investigational drug in trials for eye diseases, and sells DEXTENZA. It last closed at $6.02 on Nov 17, up 0.17% on the day. OCUL reports earnings on Thu, Feb 4, 2027. The average 12-month price target from 4 analysts is $20.75 (+244.7% from the last close), with a high of $28.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $800K, the largest $612K.

AI Auto Pilots
Is OCUL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$50.4M
−9.7% vs a year ago
Net income
−$326.8M
−648.6% margin
EPS (diluted)
−$1.44
Free cash flow
−$267.0M
−530.0% margin
Valuation
Market cap
$1.3B
220.0M shares
P/E
–
No P/E while losing money
Price to sales
26.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$530.6M
At Sep 30
Debt
$73.5M
At Sep 30
Shareholder equity
$440.9M
Shares outstanding
220.0M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $43.5M$43.5MFY2021FY2022: $51.5M$51.5MFY2022FY2023: $58.4M$58.4MFY2023FY2024: $63.7M$63.7MFY2024FY2025: $52.0M$52.0MFY2025

From OCUL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 4
2027 · Time not announced
Consensus EPS forecast
-$0.45
$13.8M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on OCUL in the past 90 days
Average 12-month target
$20.75
▲ 244.7% upside

Based on 4 analysts who set a price target on OCUL in the past 90 days. The average target is $20.75, with a high of $28.00 and a low of $14.00, compared with the last close of $6.02.

$4$13$21$30PAST 10 TRADING DAYS12-MONTH TARGETSHIGH $28AVG $20.75LOW $14Jun 10LAST CLOSE+12 MO$4$13$21$30PAST 10 DAYSTARGETSHIGH $28AVG $20.75LOW $14Jun 10LAST CLOSE+12 MO
Highest target$28.00
Average target$20.75
Lowest target$14.00
Latest rating changes
HC Wainwright & Co.Target raised
Nov 10Buy$25 → $28
NeedhamReiterated
Oct 19Buy$18
UBSInitiated
Oct 12Buy$14
NeedhamReiterated
Sep 29Buy$18
Chardan CapitalMaintained
Sep 16Buy$23
DateFirmActionRatingPrice target
Nov 10HC Wainwright & Co.Target raisedBuy$25 → $28
Oct 19NeedhamReiteratedBuy$18
Oct 12UBSInitiatedBuy$14
Sep 29NeedhamReiteratedBuy$18
Sep 16Chardan CapitalMaintainedBuy$23
Loading…

Technical Analysis

OCUL · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 10% below its 20 day and 29% below its 50 day average. It is 47% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Oct 19) at $6.00, and the nearest resistance the Pivot at $6.03.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.4%/day
Key levels
$16.4452 week high+173.1%
$8.87200 day average+47.3%
$8.79100 day average+46.0%
$7.7950 day average+29.4%
$7.24Swing high (Nov 5)+20.3%
$6.6420 day average+10.3%
$6.26Pivot R1+4.0%
$6.03Pivot+0.2%
$6.02Last close
$6.00Swing low (Oct 19)−0.3%
$5.8052 week low−3.7%
$5.79Pivot S1−3.8%
Indicators
RSI (14)35.67Weak, oversold below 30Neutral
MACD-0.40Below its signal lineBearish
Stochastic10.2Near the bottom of its rangeOversold
ADX (14)42.0Strong downtrend
Williams %R-87.6Oversold below −80, overbought above −20Oversold
CCI (20)-166.4Oversold below −100, overbought above 100Oversold
Rate of change−11.7%Change over 10 sessionsBearish
ATR (14)$0.44Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCUL

What happened before

See how OCUL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OCUL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OCUL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OCUL in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$800K
Largest print
$612K
Loading…

OCUL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲140 buying vs 113 selling
  • ▲Held by funds +0.8 pts
  • ●Funds holding +1
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding263262+0.4%
In funds' top 10660.0%
Held by funds95.0%94.2%+0.8 pts
New / increased39 / 10130 / 107+2.2%
Reduced / sold out74 / 3980 / 39−5.0%
Put/call ratio0.400.08+370.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OCUL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCUL is in one of them and how their past OCUL trades turned out.

OCUL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OCUL in an article yet. Here's the latest on the wider market.

About Ocular Therapeutix

Ocular Therapeutix is a biopharmaceutical company based in Bedford, Massachusetts, that develops and sells treatments for eye conditions. Its lead investigational product, AXPAXLI, is a drug delivered into the eye through a gel that dissolves over time, and it is being tested for wet macular degeneration and diabetic retinal disease. The company also sells DEXTENZA, an FDA-approved insert used to treat eye pain and inflammation after surgery and itching from allergic conjunctivitis.

Headquarters
Bedford, MA